Advertisement
Open Access 12-03-2025 | Current Opinion
Innovation in the Design of Clinical Trials for Infectious Diseases: Focusing on Patients Over Pathogens
Published in: Pharmaceutical Medicine
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Kaptchuk TJ, Kerr CE. Commentary: unbiased divination, unbiased evidence, and the patulin clinical trial. Int J Epidemiol. 2004;33(2):247–51.PubMedCrossRef
Kaptchuk TJ, Kerr CE. Commentary: unbiased divination, unbiased evidence, and the patulin clinical trial. Int J Epidemiol. 2004;33(2):247–51.PubMedCrossRef
2.
go back to reference Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–82.CrossRef
Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–82.CrossRef
3.
go back to reference Chalmers I, Clarke M. Commentary: the 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. Int J Epidemiol. 2004;33(2):253–60.PubMedCrossRef
Chalmers I, Clarke M. Commentary: the 1944 patulin trial: the first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. Int J Epidemiol. 2004;33(2):253–60.PubMedCrossRef
4.
go back to reference Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.PubMedPubMedCentralCrossRef
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.PubMedPubMedCentralCrossRef
5.
go back to reference Saaiq M, Ashraf B. Modifying “Pico” Question into “Picos” model for more robust and reproducible presentation of the methodology employed in a scientific study. World J Plast Surg. 2017;6(3):390–2.PubMedPubMedCentral
Saaiq M, Ashraf B. Modifying “Pico” Question into “Picos” model for more robust and reproducible presentation of the methodology employed in a scientific study. World J Plast Surg. 2017;6(3):390–2.PubMedPubMedCentral
6.
go back to reference Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.PubMedCrossRef
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.PubMedCrossRef
7.
go back to reference US Food and Drug Administration. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases: Guidance for Industry. https://www.fda.gov/files/drugs/published/Antibacterial-Therapies-for-Patients-With-an-Unmet-Medical-Need-for-the-Treatment-of-Serious-Bacterial-Diseases.pdf.
US Food and Drug Administration. Antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases: Guidance for Industry. https://www.fda.gov/files/drugs/published/Antibacterial-Therapies-for-Patients-With-an-Unmet-Medical-Need-for-the-Treatment-of-Serious-Bacterial-Diseases.pdf.
8.
go back to reference US Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. 2017.
US Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. 2017.
9.
go back to reference Doshi P. Did the FDA break its own rules in approving the antibiotic Recarbrio? BMJ. 2023;381: p1048.CrossRef
Doshi P. Did the FDA break its own rules in approving the antibiotic Recarbrio? BMJ. 2023;381: p1048.CrossRef
10.
go back to reference Finland M. Serum therapy in the treatment of lobar pneumonia. N Engl J Med. 1930;202(26):1244–7.CrossRef
Finland M. Serum therapy in the treatment of lobar pneumonia. N Engl J Med. 1930;202(26):1244–7.CrossRef
11.
go back to reference Deak D, Outterson K, Powers JH, Kesselheim AS: Progress in the fight against multidrug-resistant bacteria? A review of U.S. food and drug administration-approved antibiotics, 2010–2015. Ann Intern Med 2016.
Deak D, Outterson K, Powers JH, Kesselheim AS: Progress in the fight against multidrug-resistant bacteria? A review of U.S. food and drug administration-approved antibiotics, 2010–2015. Ann Intern Med 2016.
12.
go back to reference Mitra-Majumdar M, Powers JH, Brown BL, Kesselheim AS. Evidence at time of regulatory approval and cost of new antibiotics in 2016–19: cohort study of FDA approved drugs. BMJ Med. 2022;1(1): e000227.PubMedPubMedCentralCrossRef
Mitra-Majumdar M, Powers JH, Brown BL, Kesselheim AS. Evidence at time of regulatory approval and cost of new antibiotics in 2016–19: cohort study of FDA approved drugs. BMJ Med. 2022;1(1): e000227.PubMedPubMedCentralCrossRef
13.
go back to reference Yahav D, Tau N, Shepshelovich D. Assessment of data supporting the efficacy of new antibiotics for treating infections caused by multidrug-resistant bacteria. Clin Infect Dis. 2021;72(11):1968–74.PubMedCrossRef
Yahav D, Tau N, Shepshelovich D. Assessment of data supporting the efficacy of new antibiotics for treating infections caused by multidrug-resistant bacteria. Clin Infect Dis. 2021;72(11):1968–74.PubMedCrossRef
14.
go back to reference Powers JH. Noninferiority and equivalence trials: deciphering “similarity” of medical interventions. Stat Med. 2008;27(3):343–52.PubMedCrossRef
Powers JH. Noninferiority and equivalence trials: deciphering “similarity” of medical interventions. Stat Med. 2008;27(3):343–52.PubMedCrossRef
15.
go back to reference Kuzucan A, Powers JH, Doshi P. Antibiotics approved for marketing in populations specifically excluded from premarketing trials, 1999–2018. Mayo Clin Proc. 2020;95(12):2699–703.PubMedCrossRef
Kuzucan A, Powers JH, Doshi P. Antibiotics approved for marketing in populations specifically excluded from premarketing trials, 1999–2018. Mayo Clin Proc. 2020;95(12):2699–703.PubMedCrossRef
16.
go back to reference Dowling HF. Twixt the cup and the lip. J Am Med Assoc. 1957;165(6):657–61.PubMedCrossRef
Dowling HF. Twixt the cup and the lip. J Am Med Assoc. 1957;165(6):657–61.PubMedCrossRef
17.
go back to reference Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis. 2008;47(Suppl 3):S108-120.PubMedCrossRef
Fleming TR, Powers JH. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis. 2008;47(Suppl 3):S108-120.PubMedCrossRef
18.
go back to reference Kahlmeter G, Turnidge J. ’How To: ECOFFs—the why, the how and the don’ts of EUCAST epidemiological cutoff values’—Author’s response. Clin Microbiol Infect. 2022;28(7):1030–1.PubMedCrossRef
Kahlmeter G, Turnidge J. ’How To: ECOFFs—the why, the how and the don’ts of EUCAST epidemiological cutoff values’—Author’s response. Clin Microbiol Infect. 2022;28(7):1030–1.PubMedCrossRef
19.
go back to reference Tamma PD, Powers JH. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints? Clin Infect Dis. 2013;57(4):624–5.PubMedCrossRef
Tamma PD, Powers JH. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints? Clin Infect Dis. 2013;57(4):624–5.PubMedCrossRef
20.
go back to reference Tamma PD, Wu H, Gerber JS, Hsu AJ, Tekle T, Carroll KC, Cosgrove SE. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? Pediatr Infect Dis J. 2013;32(9):965–9.PubMedCrossRef
Tamma PD, Wu H, Gerber JS, Hsu AJ, Tekle T, Carroll KC, Cosgrove SE. Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? Pediatr Infect Dis J. 2013;32(9):965–9.PubMedCrossRef
21.
go back to reference Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it’s all relative. Clin Infect Dis. 2004;38(1):99–103.PubMedCrossRef
Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it’s all relative. Clin Infect Dis. 2004;38(1):99–103.PubMedCrossRef
22.
go back to reference Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.PubMedPubMedCentralCrossRef
Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.PubMedPubMedCentralCrossRef
23.
go back to reference Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2013;19(12):1163–8.PubMedCrossRef
Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2013;19(12):1163–8.PubMedCrossRef
24.
go back to reference Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340–7.PubMedCrossRef
Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340–7.PubMedCrossRef
25.
go back to reference Lux LJ et al. Pharmacokinetic/Pharmacodynamic measures for guiding antibiotic treatment for hospital-acquired pneumonia. http://www.ncbi.nlm.nih.gov/pubmed/25577937.
Lux LJ et al. Pharmacokinetic/Pharmacodynamic measures for guiding antibiotic treatment for hospital-acquired pneumonia. http://www.ncbi.nlm.nih.gov/pubmed/25577937.
26.
go back to reference Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–53.PubMedPubMedCentralCrossRef
Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–53.PubMedPubMedCentralCrossRef
27.
go back to reference Yahav D, Shepshelovich D, Tau N. Cost analysis of new antibiotics to treat multidrug-resistant bacterial infections: mind the gap. Infect Dis Ther. 2021;10(1):621–30.PubMedPubMedCentralCrossRef
Yahav D, Shepshelovich D, Tau N. Cost analysis of new antibiotics to treat multidrug-resistant bacterial infections: mind the gap. Infect Dis Ther. 2021;10(1):621–30.PubMedPubMedCentralCrossRef
28.
go back to reference Lawandi A, Kadri S, Powers J. Focusing on antimicrobial resistant infections—Are we missing the forest for the trees and the patients for pathogens? Front Antibiotics. 2023. https://doi.org/10.3389/frabi.2023.1329081.CrossRef
Lawandi A, Kadri S, Powers J. Focusing on antimicrobial resistant infections—Are we missing the forest for the trees and the patients for pathogens? Front Antibiotics. 2023. https://doi.org/10.3389/frabi.2023.1329081.CrossRef
29.
go back to reference Diallo OO, Baron SA, Dubourg G, Chaudet H, Halfon P, Camiade S, Comte B, Joubert S, Francois A, Seyral P, et al. Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains. Sci Rep. 2020;10(1):18262.PubMedPubMedCentralCrossRef
Diallo OO, Baron SA, Dubourg G, Chaudet H, Halfon P, Camiade S, Comte B, Joubert S, Francois A, Seyral P, et al. Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains. Sci Rep. 2020;10(1):18262.PubMedPubMedCentralCrossRef
30.
go back to reference Baquero F. Threats of antibiotic resistance: an obliged reappraisal. Int Microbiol. 2021;24(4):499–506.PubMedPubMedCentralCrossRef
Baquero F. Threats of antibiotic resistance: an obliged reappraisal. Int Microbiol. 2021;24(4):499–506.PubMedPubMedCentralCrossRef
31.
go back to reference Abat C, Fournier PE, Jimeno MT, Rolain JM, Raoult D. Extremely and pandrug-resistant bacteria extra-deaths: myth or reality? Eur J Clin Microbiol Infect Dis. 2018;37(9):1687–97.PubMedCrossRef
Abat C, Fournier PE, Jimeno MT, Rolain JM, Raoult D. Extremely and pandrug-resistant bacteria extra-deaths: myth or reality? Eur J Clin Microbiol Infect Dis. 2018;37(9):1687–97.PubMedCrossRef
32.
go back to reference Abat C, Rolain JM, Dubourg G, Fournier PE, Chaudet H, Raoult D. Evaluating the clinical burden and mortality attributable to antibiotic resistance: the disparity of empirical data and simple model estimations. Clin Infect Dis. 2017;65(suppl_1):S58–63.PubMedCrossRef
Abat C, Rolain JM, Dubourg G, Fournier PE, Chaudet H, Raoult D. Evaluating the clinical burden and mortality attributable to antibiotic resistance: the disparity of empirical data and simple model estimations. Clin Infect Dis. 2017;65(suppl_1):S58–63.PubMedCrossRef
33.
go back to reference Liao JX, Appaneal HJ, Menon A, Lopes V, LaPlante KL, Caffrey AR. Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States veterans affairs medical centers, 2011–2020. Infect Dis Ther. 2023;12(7):1835–48.PubMedPubMedCentralCrossRef
Liao JX, Appaneal HJ, Menon A, Lopes V, LaPlante KL, Caffrey AR. Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States veterans affairs medical centers, 2011–2020. Infect Dis Ther. 2023;12(7):1835–48.PubMedPubMedCentralCrossRef
34.
go back to reference Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef
35.
go back to reference Fischer WA, Wohl DA. Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival. Lancet Infect Dis. 2024;24(6):560–2.PubMedCrossRef
Fischer WA, Wohl DA. Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival. Lancet Infect Dis. 2024;24(6):560–2.PubMedCrossRef
36.
go back to reference von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS et al. Association between antibiotic exposure and systemic immune parameters in cancer patients receiving checkpoint inhibitor therapy. Cancers (Basel). 2022;14(5):1327.
von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS et al. Association between antibiotic exposure and systemic immune parameters in cancer patients receiving checkpoint inhibitor therapy. Cancers (Basel). 2022;14(5):1327.
37.
go back to reference Lovegrove MC, Geller AI, Fleming-Dutra KE, Shehab N, Sapiano MRP, Budnitz DS. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015. J Pediatric Infect Dis Soc. 2019;8(5):384–91.PubMedCrossRef
Lovegrove MC, Geller AI, Fleming-Dutra KE, Shehab N, Sapiano MRP, Budnitz DS. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015. J Pediatric Infect Dis Soc. 2019;8(5):384–91.PubMedCrossRef
38.
go back to reference Mauri L, D’Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377(14):1357–67.PubMedCrossRef
Mauri L, D’Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377(14):1357–67.PubMedCrossRef
39.
go back to reference Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–604.CrossRef
Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–604.CrossRef
40.
go back to reference Doshi P, Spence O, Kuzucan A, Powers JH. Communication of nonefficacy benefits of new drugs approved on the basis of noninferiority trials alone: cohort study of FDA and sponsor communication, 2011–2017. JAMA Intern Med. 2019;179(5):719–21.PubMedPubMedCentralCrossRef
Doshi P, Spence O, Kuzucan A, Powers JH. Communication of nonefficacy benefits of new drugs approved on the basis of noninferiority trials alone: cohort study of FDA and sponsor communication, 2011–2017. JAMA Intern Med. 2019;179(5):719–21.PubMedPubMedCentralCrossRef
41.
go back to reference Doshi P, Hur P, Jones M, Albarmawi H, Jefferson T, Morgan DJ, Spears PA, Powers JH. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med. 2017;177(10):1–8.CrossRef
Doshi P, Hur P, Jones M, Albarmawi H, Jefferson T, Morgan DJ, Spears PA, Powers JH. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med. 2017;177(10):1–8.CrossRef
42.
go back to reference Ethical Principles and Guidelines for the Protection of Human
Ethical Principles and Guidelines for the Protection of Human
43.
go back to reference Ethical Principles and Guidelines for the Protection of Human Subjects of Research: the Belmont Report. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
Ethical Principles and Guidelines for the Protection of Human Subjects of Research: the Belmont Report. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
44.
go back to reference Garattini S, Bertele’ V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet. 2007;370(9602):1875–7.PubMedCrossRef
Garattini S, Bertele’ V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet. 2007;370(9602):1875–7.PubMedCrossRef
45.
go back to reference Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRef
Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRef
46.
go back to reference Powers JH. Scientific evidence, regulatory decision making, and incentives for therapeutics in infectious diseases: the example of cefiderocol. Clin Infect Dis. 2021;72(12):e1112–4.PubMedCrossRef
Powers JH. Scientific evidence, regulatory decision making, and incentives for therapeutics in infectious diseases: the example of cefiderocol. Clin Infect Dis. 2021;72(12):e1112–4.PubMedCrossRef
47.
48.
go back to reference Doshi P, Spence O, Powers JH. Noninferiority trials. N Engl J Med. 2018;378(3):304.PubMed
Doshi P, Spence O, Powers JH. Noninferiority trials. N Engl J Med. 2018;378(3):304.PubMed
49.
go back to reference International Conference on Harmonization. Statistical principles for clinical trials E9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
International Conference on Harmonization. Statistical principles for clinical trials E9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
50.
go back to reference International Conference on Harmonization. Choice of control group and related issues in clinical trials. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
International Conference on Harmonization. Choice of control group and related issues in clinical trials. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
51.
go back to reference Morlock R, Rose J, Powers JH. Perspectives of US adults on antimicrobial trials with noninferiority designs. JAMA Netw Open. 2023;6(5): e2316297.PubMedPubMedCentralCrossRef
Morlock R, Rose J, Powers JH. Perspectives of US adults on antimicrobial trials with noninferiority designs. JAMA Netw Open. 2023;6(5): e2316297.PubMedPubMedCentralCrossRef
52.
go back to reference Belia S, Fidler F, Williams J, Cumming G. Researchers misunderstand confidence intervals and standard error bars. Psychol Methods. 2005;10(4):389–96.PubMedCrossRef
Belia S, Fidler F, Williams J, Cumming G. Researchers misunderstand confidence intervals and standard error bars. Psychol Methods. 2005;10(4):389–96.PubMedCrossRef
53.
go back to reference Hoekstra R, Morey RD, Rouder JN, Wagenmakers EJ. Robust misinterpretation of confidence intervals. Psychon Bull Rev. 2014;21(5):1157–64.PubMedCrossRef
Hoekstra R, Morey RD, Rouder JN, Wagenmakers EJ. Robust misinterpretation of confidence intervals. Psychon Bull Rev. 2014;21(5):1157–64.PubMedCrossRef
54.
go back to reference Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60(2):170–80.PubMedCrossRef
Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60(2):170–80.PubMedCrossRef
55.
go back to reference Beecher HK. Ethics and clinical research. N Engl J Med. 1966;274(24):1354–60.PubMedCrossRef
Beecher HK. Ethics and clinical research. N Engl J Med. 1966;274(24):1354–60.PubMedCrossRef
56.
go back to reference Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. IRB. 1987;9(6):7–10.PubMedCrossRef
Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. IRB. 1987;9(6):7–10.PubMedCrossRef
57.
go back to reference Odem-Davis K, Fleming TR. A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res. 2015;7(1):12–24.PubMedPubMedCentralCrossRef
Odem-Davis K, Fleming TR. A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res. 2015;7(1):12–24.PubMedPubMedCentralCrossRef
58.
go back to reference Bai AD, Komorowski AS, Lo CKL, Tandon P, Li XX, Mokashi V, Cvetkovic A, Kay VR, Findlater A, Liang L, et al. Methodological and reporting quality of noninferiority randomized controlled trials comparing antibiotic therapies: a systematic review. Clin Infect Dis. 2021;73(7):e1696–705.PubMedCrossRef
Bai AD, Komorowski AS, Lo CKL, Tandon P, Li XX, Mokashi V, Cvetkovic A, Kay VR, Findlater A, Liang L, et al. Methodological and reporting quality of noninferiority randomized controlled trials comparing antibiotic therapies: a systematic review. Clin Infect Dis. 2021;73(7):e1696–705.PubMedCrossRef
59.
go back to reference US Food and Drug Administration: Sulbactam-durlobactam (Xacduro) Intergrated Review; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000TOC.cfm.
US Food and Drug Administration: Sulbactam-durlobactam (Xacduro) Intergrated Review; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000TOC.cfm.
60.
go back to reference Li Y, He Y, Sheng Y, Wang K, Wang J, Huang J, Yang J, Zheng Q. Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs. Expert Rev Anti Infect Ther. 2013;11(12):1377–89.PubMedCrossRef
Li Y, He Y, Sheng Y, Wang K, Wang J, Huang J, Yang J, Zheng Q. Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs. Expert Rev Anti Infect Ther. 2013;11(12):1377–89.PubMedCrossRef
61.
go back to reference Drekonja DM, Trautner B, Johnson JR. Effect of 7 vs 14 days of antibiotics among afebrile men with urinary tract infection-reply. JAMA. 2021;326(20):2080–1.PubMedCrossRef
Drekonja DM, Trautner B, Johnson JR. Effect of 7 vs 14 days of antibiotics among afebrile men with urinary tract infection-reply. JAMA. 2021;326(20):2080–1.PubMedCrossRef
62.
go back to reference Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76(9):1646–54.PubMedPubMedCentralCrossRef
Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76(9):1646–54.PubMedPubMedCentralCrossRef
63.
go back to reference Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, et al. Real-world evidence—What is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.PubMedCrossRef
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, et al. Real-world evidence—What is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.PubMedCrossRef
64.
go back to reference Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546–50.PubMedPubMedCentralCrossRef
Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546–50.PubMedPubMedCentralCrossRef
65.
go back to reference Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64–74.PubMedCrossRef
Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64–74.PubMedCrossRef
66.
go back to reference Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347: f6409.PubMedCrossRef
Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347: f6409.PubMedCrossRef
67.
go back to reference Breznau N, Rinke EM, Wuttke A, Nguyen HHV, Adem M, Adriaans J, Alvarez-Benjumea A, Andersen HK, Auer D, Azevedo F, et al. Observing many researchers using the same data and hypothesis reveals a hidden universe of uncertainty. Proc Natl Acad Sci USA. 2022;119(44): e2203150119.PubMedPubMedCentralCrossRef
Breznau N, Rinke EM, Wuttke A, Nguyen HHV, Adem M, Adriaans J, Alvarez-Benjumea A, Andersen HK, Auer D, Azevedo F, et al. Observing many researchers using the same data and hypothesis reveals a hidden universe of uncertainty. Proc Natl Acad Sci USA. 2022;119(44): e2203150119.PubMedPubMedCentralCrossRef
68.
go back to reference Epling BP, Powers JH 3rd. Cefiderocol and the need for higher-quality evidence: methods matter for patients. Antimicrob Agents Chemother. 2022;66(8): e0076622.PubMedCrossRef
Epling BP, Powers JH 3rd. Cefiderocol and the need for higher-quality evidence: methods matter for patients. Antimicrob Agents Chemother. 2022;66(8): e0076622.PubMedCrossRef
69.
go back to reference Hey SP, Kesselheim AS, Patel P, Mehrotra P, Powers JH. US food and drug administration recommendations on the use of surrogate measures as end points in new anti-infective drug approvals. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2019.5451.CrossRefPubMedPubMedCentral
Hey SP, Kesselheim AS, Patel P, Mehrotra P, Powers JH. US food and drug administration recommendations on the use of surrogate measures as end points in new anti-infective drug approvals. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2019.5451.CrossRefPubMedPubMedCentral
70.
go back to reference Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy378.CrossRefPubMedPubMedCentral
Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy378.CrossRefPubMedPubMedCentral
71.
go back to reference Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, Klompas M, Dekker JP, Powers JH, Danner RL, et al. External validation of difficult-to-treat resistance prevalence and mortality risk in gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Open Forum Infect Dis. 2019;6(4): ofz110.PubMedPubMedCentralCrossRef
Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, Klompas M, Dekker JP, Powers JH, Danner RL, et al. External validation of difficult-to-treat resistance prevalence and mortality risk in gram-negative bloodstream infection using electronic health record data from 140 US hospitals. Open Forum Infect Dis. 2019;6(4): ofz110.PubMedPubMedCentralCrossRef
72.
go back to reference Strich JR, Warner S, Lai YL, Demirkale CY, Powers JH 3rd, Danner RL, Kadri SS. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1172–81.PubMedPubMedCentralCrossRef
Strich JR, Warner S, Lai YL, Demirkale CY, Powers JH 3rd, Danner RL, Kadri SS. Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1172–81.PubMedPubMedCentralCrossRef
73.
go back to reference Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241–51.PubMedCrossRef
Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241–51.PubMedCrossRef
74.
go back to reference Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187–97.PubMedCrossRef
Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387(10024):1187–97.PubMedCrossRef
75.
go back to reference Gaydos CA, Ako MC, Lewis M, Hsieh YH, Rothman RE, Dugas AF. Use of a rapid diagnostic for chlamydia trachomatis and neisseria gonorrhoeae for women in the emergency department can improve clinical management: report of a randomized clinical trial. Ann Emerg Med. 2019;74(1):36–44.PubMedCrossRef
Gaydos CA, Ako MC, Lewis M, Hsieh YH, Rothman RE, Dugas AF. Use of a rapid diagnostic for chlamydia trachomatis and neisseria gonorrhoeae for women in the emergency department can improve clinical management: report of a randomized clinical trial. Ann Emerg Med. 2019;74(1):36–44.PubMedCrossRef
76.
go back to reference Hemminki E, Paakkulainen A. The effect of antibiotics on mortality from infectious diseases in Sweden and Finland. Am J Public Health. 1976;66(12):1180–4.PubMedPubMedCentralCrossRef
Hemminki E, Paakkulainen A. The effect of antibiotics on mortality from infectious diseases in Sweden and Finland. Am J Public Health. 1976;66(12):1180–4.PubMedPubMedCentralCrossRef
77.
go back to reference Tu Q, Pu M, Li Y, Wang Y, Li M, Song L, An X, Fan H, Tong Y. Acinetobacter baumannii phages: past, present and future. Viruses. 2023;15(3):673.PubMedPubMedCentralCrossRef
Tu Q, Pu M, Li Y, Wang Y, Li M, Song L, An X, Fan H, Tong Y. Acinetobacter baumannii phages: past, present and future. Viruses. 2023;15(3):673.PubMedPubMedCentralCrossRef
78.
go back to reference Normand ST. The RECOVERY platform. N Engl J Med. 2021;384(8):757–8.PubMedCrossRef
Normand ST. The RECOVERY platform. N Engl J Med. 2021;384(8):757–8.PubMedCrossRef
79.
go back to reference Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefève G, Souweine B, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931–41.PubMedCrossRef
Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefève G, Souweine B, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931–41.PubMedCrossRef
80.
go back to reference Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506.PubMedPubMedCentralCrossRef
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492–506.PubMedPubMedCentralCrossRef
81.
go back to reference Altman DG, Bland JM. Statistics notes. Treatment allocation in controlled trials: why randomise? BMJ. 1999;318(7192):1209.PubMedPubMedCentralCrossRef
Altman DG, Bland JM. Statistics notes. Treatment allocation in controlled trials: why randomise? BMJ. 1999;318(7192):1209.PubMedPubMedCentralCrossRef
82.
go back to reference Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303.PubMedPubMedCentralCrossRef
Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303.PubMedPubMedCentralCrossRef
83.
go back to reference Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther. 2017;102(6):934–41.PubMedCrossRef
Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther. 2017;102(6):934–41.PubMedCrossRef
84.
go back to reference Dodd LE, Freidlin B, Korn EL. Platform trials - beware the noncomparable control group. N Engl J Med. 2021;384(16):1572–3.PubMedPubMedCentralCrossRef
Dodd LE, Freidlin B, Korn EL. Platform trials - beware the noncomparable control group. N Engl J Med. 2021;384(16):1572–3.PubMedPubMedCentralCrossRef
85.
go back to reference Tarolli CG, Andrzejewski K, Zimmerman GA, Bull M, Goldenthal S, Auinger P, O’Brien M, Dorsey ER, Biglan K, Simuni T. Feasibility, reliability, and value of remote video-based trial visits in Parkinson’s disease. J Parkinsons Dis. 2020;10(4):1779–86.PubMedCrossRef
Tarolli CG, Andrzejewski K, Zimmerman GA, Bull M, Goldenthal S, Auinger P, O’Brien M, Dorsey ER, Biglan K, Simuni T. Feasibility, reliability, and value of remote video-based trial visits in Parkinson’s disease. J Parkinsons Dis. 2020;10(4):1779–86.PubMedCrossRef
86.
go back to reference Califf RM. Pragmatic clinical trials: emerging challenges and new roles for statisticians. Clin Trials. 2016;13(5):471–7.PubMedCrossRef
Califf RM. Pragmatic clinical trials: emerging challenges and new roles for statisticians. Clin Trials. 2016;13(5):471–7.PubMedCrossRef
87.
go back to reference Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.PubMedCrossRef
Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.PubMedCrossRef
88.
go back to reference Granholm A, Anthon CT, Kjær MN, Maagaard M, Kaas-Hansen BS, Sivapalan P, Schjørring OL, Andersen LW, Mathiesen O, Strøm T, et al. Patient-important outcomes other than mortality in contemporary ICU trials: a scoping review. Crit Care Med. 2022;50(10):e759–71.PubMedCrossRef
Granholm A, Anthon CT, Kjær MN, Maagaard M, Kaas-Hansen BS, Sivapalan P, Schjørring OL, Andersen LW, Mathiesen O, Strøm T, et al. Patient-important outcomes other than mortality in contemporary ICU trials: a scoping review. Crit Care Med. 2022;50(10):e759–71.PubMedCrossRef
89.
go back to reference Hartz A, He T, Wallace R, Powers J. Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open 2013, 3(7).
Hartz A, He T, Wallace R, Powers J. Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open 2013, 3(7).
90.
go back to reference Montezuma-Rusca JM, Powers JH, Follmann D, Wang J, Sullivan B, Williamson PR. Early fungicidal activity as a candidate surrogate endpoint for all-cause mortality in cryptococcal meningitis: a systematic review of the evidence. PLoS One. 2016;11(8): e0159727.PubMedPubMedCentralCrossRef
Montezuma-Rusca JM, Powers JH, Follmann D, Wang J, Sullivan B, Williamson PR. Early fungicidal activity as a candidate surrogate endpoint for all-cause mortality in cryptococcal meningitis: a systematic review of the evidence. PLoS One. 2016;11(8): e0159727.PubMedPubMedCentralCrossRef
91.
go back to reference Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973–84.PubMedPubMedCentralCrossRef
Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973–84.PubMedPubMedCentralCrossRef
92.
go back to reference Powers JH. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. Pharmacotherapy. 2005;25(12 Pt 2):109S-123S.PubMedCrossRef
Powers JH. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. Pharmacotherapy. 2005;25(12 Pt 2):109S-123S.PubMedCrossRef
93.
go back to reference Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, et al. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza Other Respir Viruses. 2024;18(2): e13236.PubMedPubMedCentralCrossRef
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, et al. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age. Influenza Other Respir Viruses. 2024;18(2): e13236.PubMedPubMedCentralCrossRef
94.
go back to reference Satram S, Ghafoori P, Reyes CM, Keeley TJH, Birch HJ, Brintziki D, Aldinger M, Alexander E, Lopuski A, Sarkis EH, et al. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. J Patient Rep Outcomes. 2023;7(1):92.PubMedPubMedCentralCrossRef
Satram S, Ghafoori P, Reyes CM, Keeley TJH, Birch HJ, Brintziki D, Aldinger M, Alexander E, Lopuski A, Sarkis EH, et al. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. J Patient Rep Outcomes. 2023;7(1):92.PubMedPubMedCentralCrossRef
95.
go back to reference Richard SA, Epsi NJ, Lindholm DA, Malloy AMW, Maves RC, Berjohn CM, Lalani T, Smith AG, Mody RM, Ganesan A, et al. COVID-19 patient-reported symptoms using FLU-PRO plus in a cohort study: associations with infecting genotype, vaccine history, and return to health. Open Forum Infect Dis. 2022;9(7): ofac275.PubMedPubMedCentralCrossRef
Richard SA, Epsi NJ, Lindholm DA, Malloy AMW, Maves RC, Berjohn CM, Lalani T, Smith AG, Mody RM, Ganesan A, et al. COVID-19 patient-reported symptoms using FLU-PRO plus in a cohort study: associations with infecting genotype, vaccine history, and return to health. Open Forum Infect Dis. 2022;9(7): ofac275.PubMedPubMedCentralCrossRef
96.
go back to reference Yu J, Powers JH, Vallo D, Falloon J. Evaluation of efficacy endpoints for a phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation. Value Health. 2020;23(2):227–35.PubMedCrossRef
Yu J, Powers JH, Vallo D, Falloon J. Evaluation of efficacy endpoints for a phase IIb study of a respiratory syncytial virus vaccine in older adults using patient-reported outcomes with laboratory confirmation. Value Health. 2020;23(2):227–35.PubMedCrossRef
97.
go back to reference Powers JH, Howard K, Saretsky T, Clifford S, Hoffmann S, Llorens L, Talbot G. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(Suppl 2):S52-56.PubMedPubMedCentralCrossRef
Powers JH, Howard K, Saretsky T, Clifford S, Hoffmann S, Llorens L, Talbot G. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis. 2016;63(Suppl 2):S52-56.PubMedPubMedCentralCrossRef
98.
go back to reference Powers JH, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A, Molsen E, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2–14.PubMedPubMedCentralCrossRef
Powers JH, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A, Molsen E, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2–14.PubMedPubMedCentralCrossRef
99.
go back to reference Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG, et al. Desirability of Outcome Ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clin Infect Dis. 2015. https://doi.org/10.1093/cid/civ495.CrossRefPubMedPubMedCentral
Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG, et al. Desirability of Outcome Ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clin Infect Dis. 2015. https://doi.org/10.1093/cid/civ495.CrossRefPubMedPubMedCentral
100.
go back to reference Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–40.PubMedCrossRef
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–40.PubMedCrossRef
101.
go back to reference Shankar-Hari M, Rubenfeld GD. Understanding long-term outcomes following sepsis: implications and challenges. Curr Infect Dis Rep. 2016;18(11):37.PubMedPubMedCentralCrossRef
Shankar-Hari M, Rubenfeld GD. Understanding long-term outcomes following sepsis: implications and challenges. Curr Infect Dis Rep. 2016;18(11):37.PubMedPubMedCentralCrossRef
102.
go back to reference Guetterman TC. Basics of statistics for primary care research. Fam Med Community Health. 2019;7(2): e000067.PubMedPubMedCentralCrossRef
Guetterman TC. Basics of statistics for primary care research. Fam Med Community Health. 2019;7(2): e000067.PubMedPubMedCentralCrossRef
103.
go back to reference Emerson SS, Fleming TR. Adaptive methods: telling “the rest of the story.” J Biopharm Stat. 2010;20(6):1150–65.PubMedCrossRef
Emerson SS, Fleming TR. Adaptive methods: telling “the rest of the story.” J Biopharm Stat. 2010;20(6):1150–65.PubMedCrossRef
104.
go back to reference Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT. Design of a randomized controlled trial for ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study. J Infect Dis. 2016;213(12):1906–13.PubMedPubMedCentralCrossRef
Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT. Design of a randomized controlled trial for ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study. J Infect Dis. 2016;213(12):1906–13.PubMedPubMedCentralCrossRef
105.
go back to reference Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ. 2001;322(7292):989–91.PubMedPubMedCentralCrossRef
Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ. 2001;322(7292):989–91.PubMedPubMedCentralCrossRef
106.
go back to reference Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–9.PubMedCrossRef
Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–9.PubMedCrossRef
107.
go back to reference O’Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials. 1997;18(6):550–6 (discussion 561-557).PubMedCrossRef
O’Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials. 1997;18(6):550–6 (discussion 561-557).PubMedCrossRef
108.
go back to reference Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest. 2004;126(1):314–5 (author reply 315-316).PubMedCrossRef
Powers JH, Ross DB, Lin D, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest. 2004;126(1):314–5 (author reply 315-316).PubMedCrossRef
109.
go back to reference Evans S, Rubin DB, Powers JH, Follmann D. Analysis populations in anti-infective clinical trials: whom to analyze? Stat Commun Infect Dis. 2018. https://doi.org/10.1515/scid-2017-0002.CrossRefPubMedPubMedCentral
Evans S, Rubin DB, Powers JH, Follmann D. Analysis populations in anti-infective clinical trials: whom to analyze? Stat Commun Infect Dis. 2018. https://doi.org/10.1515/scid-2017-0002.CrossRefPubMedPubMedCentral
110.
go back to reference Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.PubMedCrossRef
Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81.PubMedCrossRef
Metadata
- Title
- Innovation in the Design of Clinical Trials for Infectious Diseases: Focusing on Patients Over Pathogens
- Authors
-
John H. Powers III
Robert J. O’Connell
- Publication date
- 12-03-2025
- Publisher
- Springer International Publishing
- Published in
-
Pharmaceutical Medicine
Print ISSN: 1178-2595
Electronic ISSN: 1179-1993 - DOI
- https://doi.org/10.1007/s40290-025-00552-3